Pharsight

Koselugo patents expiration

KOSELUGO's oppositions filed in EPO

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7425637 ASTRAZENECA N3 alkylated benzimidazole derivatives as MEK inhibitors
Mar, 2025

(8 months from now)

US8178693 ASTRAZENECA N3 alkylated benzimidazole derivatives as MEK inhibitors
Mar, 2025

(8 months from now)

US9156795 ASTRAZENECA Hydrogen sulfate salt
Dec, 2026

(2 years from now)

US9562017 ASTRAZENECA Hydrogen sulfate salt
Dec, 2026

(2 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11813246 ASTRAZENECA Pharmaceutical composition
Mar, 2029

(4 years from now)

Koselugo is owned by Astrazeneca.

Koselugo contains Selumetinib Sulfate.

Koselugo has a total of 5 drug patents out of which 0 drug patents have expired.

Koselugo was authorised for market use on 10 April, 2020.

Koselugo is available in capsule;oral dosage forms.

Koselugo can be used as treatment of pediatric patients 2 years of age and older with neurofibromatosis type 1 (nf1) who have symptomatic, inoperable plexiform neurofibromas (pn).

Drug patent challenges can be filed against Koselugo from 10 April, 2024.

The generics of Koselugo are possible to be released after 26 March, 2029.

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Apr 10, 2025
Orphan Drug Exclusivity(ODE-288) Apr 10, 2027

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using SELUMETINIB SULFATE ingredient

NCE-1 date:

10 April, 2024

Market Authorisation Date:

10 April, 2020

Treatment:

Treatment of pediatric patients 2 years of age and older with neurofibromatosis type 1 (nf1) who have symptomatic, inoperable plexiform neurofibromas (pn)

Dosage:

CAPSULE;ORAL

More Information on Dosage

KOSELUGO family patents

Family Patents